[Coronary heart disease - what is of importance after coronary intervention?]

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Ticagrelor, a P2Y12-receptor antagonist, is now approved in the EU for post-coronary intervention therapy.
• Existing agents include clopidogrel and prasugrel, forming the basis for dual antithrombotic strategies.

Purpose of the Study:

• To outline current European Union guidelines for dual antithrombotic therapy following coronary interventions.
• To detail treatment durations based on stent type (bare-metal vs. drug-eluding) and clinical presentation (elective vs. acute coronary syndrome).
• To address specific considerations for triple-drug therapy and perioperative management.

Main Methods:

• Review of European Union drug approvals and clinical guidelines.
• Analysis of recommended durations for dual antithrombotic therapy (acetylsalicylic acid plus a P2Y12 inhibitor).
• Consideration of drug interactions and perioperative management strategies.

Main Results:

• Dual antithrombotic therapy duration varies: 4 weeks for bare-metal stents, at least 6 months for drug-eluding stents with acetylsalicylic acid (ASA) plus clopidogrel.
• Post-acute coronary syndrome, ASA plus clopidogrel (or prasugrel/ticagrelor) is recommended for 12 months.
• Triple-drug therapy for urgent anticoagulation should be minimized; prasugrel and ticagrelor can be co-prescribed with proton-pump inhibitors.
• Preoperative management of dual antiplatelet therapy requires careful planning to avoid premature withdrawal.

Conclusions:

• Current guidelines provide specific durations for dual antithrombotic therapy post-coronary intervention, tailored to stent type and patient condition.
• The introduction of ticagrelor expands therapeutic options, necessitating adherence to established treatment protocols.
• Safe and effective perioperative management is crucial for patients on dual antiplatelet therapy.